Press "Enter" to skip to content

In controversial move, FDA backs first new Alzheimer’s drug in nearly 20 years

The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer’s disease — despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment.

The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer’s disease — despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *